用户名:  密码:   
网站首页即时通讯活动公告最新消息科技前沿学人动向两岸三地人在海外历届活动关于我们联系我们申请加入
栏目导航 — 美国华裔教授专家网最新消息海外近报
关键字  范围   
 
FDA Recently Approved Devices
2020/9/6 22:57:05 | 浏览:133 | 评论:0

FDA Recently Approved Devices

Recently Approved Devices

The FDA has recently approved the following devices to be marketed.
FDA Recently Approved Devices
 
The prodisc® L Total Disc Replacement(prodisc® L)is intended to replace damaged intervertebral discs in a patient’s lower back(lumbar spine). The prodisc® L consists of three implant components; two metallic(cobalt-chrome)endplates and a plastic(ultra-high molecular weight polyethylene)inlay. This approval expands the indication for use of the prodisc® L to include treatment of up to two consecutive lumbar spinal sections(levels)from L3-S1.
FDA Recently Approved Devices
 
The Tack Endovascular System®(4F, 1.5-4.5mm)is intended to repair a tear(dissection)in the inside lining of a blood vessel that may have occurred following a procedure(balloon angioplasty)to improve blood flow by widening a blocked or narrowed blood vessel in the leg below the knee. The Tack Endovascular System®(4F, 1.5-4.5mm)consists of four self-expanding “Tack” implants made of a nickel-titanium alloy(nitinol)and a delivery catheter system. The delivery catheter is a long, thin, tube-like device used to deliver the Tack(s)into the artery.
FDA Recently Approved Devices
 
The Inspire® Upper Airway Stimulation(UAS)system is an implantable nerve stimulator used to treat moderate to severe obstructive sleep apnea(OSA). The Inspire® UAS system consists of implanted components including the implantable pulse generator(IPG), stimulation lead, and sensing lead and external components such as the physician programmer and the patient programmer. This approval expands the indications for use of the Inspire® UAS in patients between the ages of 18 and 21with moderate to severe OSA who:Do not have complete blockage of the upper airway; Are not able, or not effectively treated by, the removal of tonsils and other soft tissue behind the nose; Have been confirmed to fail, or cannot tolerate, PAP therapy despite attempts to improve compliance; Have followed standard of care in considering all other alternative/adjunct therapies.
FDA Recently Approved Devices
 
The therascreen® BRAF V600E RGQ PCR Kit is a laboratory test doctors use to detect the V600E mutation in the BRAF gene in tumor tissue from patients with metastatic colorectal cancer. Identifying these mutations will help patients with metastatic colorectal cancer get personalized treatments that target these genetic changes. BRAFTOVI®(encorafenib)in combination with cetuximab are drugs used to treat patients with metastatic colorectal cancer.  The presence of BRAF V600E mutations in patients with metastatic colorectal cancer is associated with a response to treatment with BRAFTOVI®(encorafenib)in combination with cetuximab.  The therascreen® BRAF V600E RGQ PCR Kit helps doctors identify patients with metastatic colorectal cancer who should be treated with BRAFTOVI®(encorafenib)+ cetuximab.
FDA Recently Approved Devices
 
FoundationOne® CDx(F1CDx)is a laboratory test designed to detect genetic variations in 324 genes, including FGFR2 gene variation, in tumor tissue. F1CDx is a companion diagnostic that was originally approved for the detection of genetic variations in patients who may be eligible for treatment with one of fifteen FDA-approved therapies for non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, and ovarian cancer. This approval expands the indications for use of the F1CDx test to include bile duct cancer patients with genetic variationsin the FGFR2 gene. Identifying the genetic variations in FGFR2 will help patients with bile duct cancer get personalized treatment with PEMAZYRE®(pemigatinib).
FDA Recently Approved Devices
 
The TREO® Abdominal Stent-Graft System is used to repair a weakened and bulging section(aneurysm)of the aorta(largest artery in the abdomen)below the renal arteries. The system consists of a tube-shaped implant(nitinol, polyester, and platinum-iridium)and a delivery catheter.
FDA Recently Approved Devices
 
FoundationOne® CDx(F1CDx)is a laboratory test designed to detect genetic variations in 324 genes, including the MET gene, in tumor tissue. F1CDx is a companion diagnostic that was originally approved for the detection of genetic variations in patients who may be eligible for treatment with one of fifteen FDA-approved therapies for non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, and ovarian cancer. This approval expands the indications for use of the F1CDx test to include lung cancer patients with certain genetic mutations in the MET gene in tumor tissue who may benefit from treatment with TABRECTA®(capmatinib). Identifying these changes will help patients with lung cancer get personalized treatment with TABRECTA®(capmatinib).
FDA Recently Approved Devices
 
The HeartStart FR3 Defibrillator is a battery-powered automated external defibrillator(AED). The HeartStart FR3 AED is indicated for use on people who have had a sudden loss of heart function(sudden cardiac arrest or SCA).
FDA Recently Approved Devices
 
The Philips HeartStart FRx Defibrillator(Model 861304)is a battery-powered automated external defibrillator(AED). The FRx AED is indicated for use on potential victims of sudden loss of heart function(sudden cardiac arrest or SCA).
FDA Recently Approved Devices
 
FoundationOne®(F1CDx)is a laboratory test designed to detect genetic variations in 324 genes and two genomic signatures in addition to homologous recombination repair(HRR)genes in tumor tissue. F1CDx is a companion diagnostic that was originally approved for the detection of genetic mutations in patients who may benefit from one of fifteen FDA-approved therapies for non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, and ovarian cancer. This approval expands the indications for use of the F1CDx test to include prostate cancer patients with certain genetic mutations in the HRR genes. In prostate cancer, mutations in the HRR genes cause abnormal functioning of the HRR proteins resulting in defective homologous DNA repair. Identifying these genetic alterations will help prostate cancer patients to get personalized treatment with Lynparza(olaparib).
FDA Recently Approved Devices
 
The PD-L1 IHC 28-8 pharmDx is a lab test doctors can use to identify if patients with non-small cell lung cancer(NSCLC)have the protein called programmed cell death ligand 1(PD-L1)in their cancer.  This lab test was previously approved to identify the PD-L1 protein in patients with non-squamous lung, urothelial, and head or neck squamous cell cancer for treatment with the drug, OPDIVO®(nivolumab). This approval expands the indications for use for this test for determining whether patients with NSCLC should be treated with the drugs, OPDIVO®(nivolumab)and YERVOY®(ipilimumab).

(no image available)
 
JUVÉDERM® VOLUMA™ XC is a gel implant(dermal filler)that is injected into specific areas of facial tissue. It consists of crosslinked hyaluronic acid(HA)made by the Streptococcus species of bacteria, formulated to a concentration of 20 mg/mL with 0.3% of the drug lidocaine as a numbing agent.  This product was previously approved for injection into facial tissue to temporarily restore volume and fullness to the areas of the mid-face, which includes the cheeks and nearby regions confined to the middle portion of the face. This approval expands the use of this product to include the chin region.
FDA Recently Approved Devices
 
FoundationOne®CDx(F1CDx)is a laboratory test designed to detect genetic variations in 324 genes in addition to select gene rearrangements and other biomarkers, such as tumor mutational burden(TMB), in the genomic makeup of a tumor. F1CDx is a companion diagnostic that was originally approved for the detection of genetic mutations in patients who may benefit from one of fifteen FDA-approved therapies for non-small cell lung cancer, melanoma, breast cancer, colorectal cancer, and ovarian cancer. This approval expands the indications for use of the F1CDx test to include solid tumor patients who have high tumor mutational burden(TMB). The TMB score comes from finding the number of mutations per megabase(length of a genome segment)in the tumor DNA. Identifying tumors with high levels of TMB will help patients with solid tumors get personalized treatment with KEYTRUDA®(pembrolizumab).
FDA Recently Approved Devices
 
The cobas® EZH2 Mutation Test is a laboratory test designed to detect specific mutations in the EZH2 gene in tumor tissue taken from patients with follicular lymphoma. Identifying these mutations will help doctors identify patients with follicular lymphoma who should be considered for treatment with TAZVERIK™(tazemetostat).
FDA Recently Approved Devices
 
The Arctic Front Advance and Artic Front Advance Pro Cardiac Cryablation Catheters are balloon-tipped catheters that use cold energy to treat a condiction called atrial fibrillation(AF), which is an abnormal heart rhythm causing fast and irregular heartbeats. The Freezor Max Cardiac Cryoablation Catheter is a secondary catheter that also uses cold energy to treat areas of the heart that the balloon-tipped catheters can not reach. The CryoConsole is the source of the gas used to make both catheters cold. The FDA previously approved these catheters to treat patients with AF episodes that begin suddently and then stop on their own or with treatment within seven days(paroxysmal AF). This approval expands the indications for use to treat patients with AF episdoes that last for more than seven days but less than six months(persistent atrial fibrillation of less than six months duration). Compared with paroxysmal AF, persistent AF is often harder to treat.
相关栏目:『海外近报
《大西洋月刊》:大选将如何可能让美国崩溃 2020-09-26 [84]
Robert Harrison:混合式学习(Blended Learning)的好处 2020-09-24 [92]
2020美国大选:班农拒绝被退场 2020-09-20 [162]
美国联邦调查局长出席众院“全球威胁”听证会 2020-09-20 [131]
美国雅虎新闻网:CIA在一场针对中国的行动中 4名特工全部丧生 2020-09-20 [114]
芬兰在2020年完成废除数学课 2020-09-16 [182]
疫情下的博士后有多惨?《Nature》调查给出7大结果 2020-09-13 [145]
德国强大的真正逻辑:培养团队合作的意识,让孩子成为一个完整的人 2020-09-12 [143]
美国科技智库(ITIF)发布报告:《与中国竞争:战略框架》 2020-09-09 [561]
人类生殖系基因组编辑临床应用国际委员会:基因组编辑还未能安全用于人类 2020-09-07 [123]
相关栏目更多文章
最新图文:
:涉嫌学术造假  肯塔基大学开除史香林和张卓教授夫妇 :诚邀参加南京医科大学2019年国际青年学者论坛 (12/18-21) :引力波天文台或有助搜寻暗物质粒子 :美国正式发布Wi-Fi 6标准:密集网络环境显优势 :Sail Through the Mist - SoCal Innovation Forum 2019(10/5) 管清友 朱振鑫:中国式投资骗局全览 马亮:做院长就能够发更多论文?论文发表是不是一场“权力的游戏”? 游天龙:《唐人街》是如何炼成的:UCLA社会学教授周敏的学术之路
更多最新图文
更多《即时通讯》>>
 
打印本文章
 
您的名字:
电子邮件:
留言内容:
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
  
关于我们联系我们申请加入后台管理设为主页加入收藏
美国华裔教授专家网版权所有,谢绝拷贝。如欲选登或发表,请与美国华裔教授专家网联系。
Copyright © 2020 ScholarsUpdate.com. All Rights Reserved.